Swiss biotech AC Immune posted interim biomarker and safety data from its Phase II active immunotherapy program targeting alpha‑synuclein in early Parkinson’s disease. The company reported reductions in disease‑related biomarkers (CSF alpha‑synuclein and neurofilament light) and a tolerable safety profile, prompting plans for regulator discussions to potentially accelerate development timelines. AC Immune presented datasets at scientific meetings and in corporate releases; investigators emphasize the signals are preliminary and clinical benefit remains to be confirmed in longer follow‑up. The filings position AC Immune to seek regulatory feedback while biopharma competitors eye immunotherapy and passive antibody approaches in neurodegeneration.